

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2008

MannKind Corporation

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation)

000-50865

(Commission File Number)

13-3607736

(IRS Employer
Identification No.)

**28903 North Avenue Paine
Valencia, California**

(Address of principal executive offices)

91355

(Zip Code)

Registrant's Telephone Number, Including Area Code: **(661) 775-5300**

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

TABLE OF CONTENTS

[Item 2.02 Results of Operations and Financial Condition](#)

[Item 9.01 Financial Statements and Exhibits](#)

[SIGNATURE](#)

[EXHIBIT INDEX](#)

[EXHIBIT 99.1](#)

[Table of Contents](#)

Item 2.02 Results of Operations and Financial Condition

On May 5, 2008, MannKind Corporation issued a press release announcing its financial results for the first quarter of 2008. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits. The following exhibit is furnished herewith:

99.1 Press Release of MannKind Corporation dated May 5, 2008, reporting MannKind’s financial results for the first quarter of 2008.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MANKIND CORPORATION

By: /s/ MATTHEW J. PFEFFER

Name: Matthew J. Pfeffer

Title: Corporate Vice President and Chief Financial
Officer

Dated: May 5, 2008

EXHIBIT INDEX

Number Description

99.1 Press Release of MannKind Corporation dated May 5, 2008, reporting MannKind's financial results for the first quarter of 2008.

**Company Contact:**

Matthew Pfeffer

Chief Financial Officer

661-295-4784

mpfeffer@mannkindcorp.com**MANNKIND CORPORATION REPORTS FIRST QUARTER FINANCIAL RESULTS****- Conference Call Today at 5:00 p.m. EDT -**

VALENCIA, Calif., May 5, 2008 – MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter ended March 31, 2008.

For the first quarter of 2008, total operating expenses were \$74.1 million, compared to \$77.3 million for the first quarter of 2007. Research and development (R&D) expenses decreased by \$5.3 million to \$58.4 million for the first quarter of 2008 compared to the first quarter of 2007, primarily due to lower clinical trial costs and associated packaging costs for clinical materials, partially offset by higher stock compensation expense. General and administrative (G&A) expenses increased by \$2.1 million to \$15.6 million for the first quarter of 2008 compared to the first quarter of 2007 primarily due to additional patent expenses.

The net loss applicable to common stockholders for the first quarter of 2008 was \$71.4 million, or \$0.70 per share based on 101.4 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of \$73.1 million, or \$1.00 per share based on 73.4 million weighted average shares outstanding for the first quarter of 2007.

Cash and cash equivalents were \$269.1 million at March 31, 2008 and \$368.3 million at December 31, 2007.

Conference Call

MannKind management will host a conference call to discuss these results today at 5:00 p.m. EDT. To participate in the call, please dial (800) 857-0373 or (210) 839-8507. To listen to the call via the internet, please visit www.mannkindcorp.com. The web site replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (866) 457-6651 or (203) 369-1300.

Presenting from the Company will be:

- Chairman and Chief Executive Officer Alfred Mann
- President and Chief Operating Officer Hakan Edstrom
- Corporate Vice President and Chief Financial Officer Matthew Pfeffer
- Corporate Vice President and Chief Scientific Officer Peter Richardson

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere® Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit www.mannkindcorp.com.

(Tables to follow)

MannKind Corporation
Condensed Statements of Operations
(Unaudited)
(in thousands, except per share amounts)

	Three Months Ended March 31,	
	2008	2007
Revenue	\$ 20	\$ 10
Operating expenses:		
Research and development	58,445	63,788
General and administrative	15,640	13,550
Total operating expenses	74,085	77,338
Loss from operations	(74,065)	(77,328)
Other income	60	52
Interest expense on senior convertible notes	(337)	(1,145)
Interest income	2,921	5,280
Loss before provision for income taxes	(71,421)	(73,141)
Income taxes	—	—
Net loss applicable to common stockholders	\$ (71,421)	\$ (73,141)
Net loss per share applicable to common stockholders — basic and diluted	\$ (0.70)	\$ (1.00)
Shares used to compute basic and diluted net loss per share applicable to common stockholders	101,409	73,388

MannKind Corporation
Condensed Balance Sheets
(Unaudited)
(in thousands)

	<u>March 31,</u> <u>2008</u>	<u>December 31,</u> <u>2007</u>
Assets		
Current assets:		
Cash and cash equivalents	\$ 269,079	\$ 368,285
State research and development tax credit exchange receivable – current	—	831
Prepaid expenses and other current assets	<u>8,004</u>	<u>9,596</u>
Total current assets	277,083	378,712
Property and equipment – net	185,895	162,683
State research and development tax credit exchange receivable - - net of current portion	1,875	1,500
Other assets	<u>549</u>	<u>548</u>
Total	<u>\$ 465,402</u>	<u>\$ 543,443</u>
Liabilities and Stockholders' Equity		
Current liabilities	\$ 55,447	\$ 67,558
Other liabilities	—	24
Senior convertible notes	111,882	111,761
Stockholders' equity	<u>298,073</u>	<u>364,100</u>
Total	<u>\$ 465,402</u>	<u>\$ 543,443</u>

###